{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:50:02Z","timestamp":1787064602939,"version":"build-2736575974"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Frederick Banting and Charles Best Canada Graduate Scholarship-Master\u2019s"},{"name":"Pfizer Chair Research Award"},{"DOI":"10.13039\/501100003579","name":"University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003579","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Psoriasis (Ps) is an inflammatory skin disease affecting over 8 million people in the USA and Canada. Approximately a quarter of patients with Ps have an inflammatory arthritis termed psoriatic arthritis (PsA). Psoriatic disease encompassing both Ps and PsA is regarded as an immune-mediated inflammatory disease, exhibiting both autoimmune and autoinflammatory features. Innate immune cell activation promotes inflammation and the cellular infiltrate in inflamed tissue is predominantly lymphocytic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Content<\/jats:title>\n                    <jats:p>A narrative review of the current literature on the presence and clinical significance of autoantibodies found in psoriatic disease are presented. The frequency of several autoantibodies in Ps and PsA patients as well as their association with disease diagnosis, disease activity, and treatment response are reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Despite historically described as a rheumatoid factor negative (seronegative) disease, an array of autoantibodies has been identified in patients with psoriatic disease. Many of the autoantibodies reviewed are elevated in Ps and PsA patients and are associated with disease activity, treatment response, and cardiovascular disease risk. The identification of autoantibodies in Ps and PsA patients points to an autoimmune component potentially playing a role in psoriatic disease; however, additional evidence is needed to determine the clinical utility of these autoantibodies and their contribution to disease pathogenesis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jalm\/jfab120","type":"journal-article","created":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T09:40:37Z","timestamp":1632994837000},"page":"281-293","source":"Crossref","is-referenced-by-count":11,"title":["Autoantibodies in Psoriatic Disease"],"prefix":"10.1093","volume":"7","author":[{"given":"John","family":"Koussiouris","sequence":"first","affiliation":[{"name":"Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Ontario, Canada"},{"name":"Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8297-0275","authenticated-orcid":false,"given":"Vinod","family":"Chandran","sequence":"additional","affiliation":[{"name":"Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Ontario, Canada"},{"name":"Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada"},{"name":"Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada"},{"name":"Department of Medicine, Memorial University, St. John's, Newfoundland and Labrador, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,1,5]]},"reference":[{"key":"2022010916492048500_jfab120-B1","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.jaad.2013.12.018","article-title":"Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey","volume":"70","author":"Lebwohl","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"2022010916492048500_jfab120-B2","doi-asserted-by":"crossref","DOI":"10.1093\/med\/9780198737582.001.0001","volume-title":"Oxford textbook of psoriatic arthritis","author":"FitzGerald","year":"2018"},{"key":"2022010916492048500_jfab120-B3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jaad.2018.06.027","article-title":"Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies","volume":"80","author":"Alinaghi","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2022010916492048500_jfab120-B4","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3899\/jrheum.190119","article-title":"The genetics of psoriasis and psoriatic arthritis","volume":"95","author":"O'Rielly","year":"2019","journal-title":"J Rheumatol Suppl"},{"key":"2022010916492048500_jfab120-B5","doi-asserted-by":"crossref","first-page":"e12945","DOI":"10.1111\/sji.12945","article-title":"Current knowledge on autoantigens and autoantibodies in psoriasis","volume":"92","author":"Ten Bergen","year":"2020","journal-title":"Scand J Immunol"},{"key":"2022010916492048500_jfab120-B6","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.3906\/sag-2011-235","article-title":"Autoimmunity in psoriatic arthritis: pathophysiological and clinical aspects","volume":"51","author":"Emmungil","year":"2021","journal-title":"Turk J Med Sci"},{"key":"2022010916492048500_jfab120-B7","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.1038\/s41467-020-18513-6","article-title":"Single-cell sequencing reveals clonal expansions of pro-inflammatory synovial CD8 T cells expressing tissue-homing receptors in psoriatic arthritis","volume":"11","author":"Penkava","year":"2020","journal-title":"Nat Commun"},{"key":"2022010916492048500_jfab120-B8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/br.2020.1343","article-title":"Assessment of serum levels of anti-cyclic citrullinated peptide antibodies in patients with psoriatic arthritis: a cross-sectional study in a Brazilian cohort","volume":"13","author":"Gruber","year":"2020","journal-title":"Biomed Rep"},{"key":"2022010916492048500_jfab120-B9","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00393-019-0666-z","article-title":"Anti-cyclic citrullinated peptide antibody in psoriatic arthritis: a meta-analysis of its frequency and association with clinical features","volume":"79","author":"Kim","year":"2020","journal-title":"Z Rheumatol"},{"key":"2022010916492048500_jfab120-B10","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1136\/ard.2005.040998","article-title":"Antibodies against cyclic citrullinated peptide (CCP) in psoriatic patients with or without joint inflammation","volume":"65","author":"Alenius","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"2022010916492048500_jfab120-B11","doi-asserted-by":"crossref","first-page":"474028","DOI":"10.1155\/2013\/474028","article-title":"Higher levels of autoantibodies targeting mutated citrullinated vimentin in patients with psoriatic arthritis than in patients with psoriasis vulgaris","volume":"2013","author":"Dalmady","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"2022010916492048500_jfab120-B12","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/14397595.2019.1586085","article-title":"Association of anti-cyclic citrullinated peptide antibody with clinical features in patients with psoriatic arthritis","volume":"30","author":"Hagiwara","year":"2020","journal-title":"Mod Rheumatol"},{"key":"2022010916492048500_jfab120-B13","first-page":"376","article-title":"Anti-cyclic citrullinated peptide antibodies in psoriatic arthritis\u2013cross-sectional study and literature review","volume":"6","author":"Popescu","year":"2013","journal-title":"J Med Life"},{"key":"2022010916492048500_jfab120-B14","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.autrev.2015.08.003","article-title":"Auto-reactions, autoimmunity and psoriatic arthritis","volume":"14","author":"Chimenti","year":"2015","journal-title":"Autoimmun Rev"},{"key":"2022010916492048500_jfab120-B15","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.cca.2020.07.037","article-title":"Autoantibodies against specific nuclear antigens are present in psoriatic disease and are diminished by secukinumab","volume":"510","author":"Patrikiou","year":"2020","journal-title":"Clin Chim Acta"},{"key":"2022010916492048500_jfab120-B16","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1136\/ard.2004.031286","article-title":"Autoantibodies in biological agent naive patients with psoriatic arthritis","volume":"64","author":"Johnson","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2022010916492048500_jfab120-B17","doi-asserted-by":"crossref","first-page":"e0134218","DOI":"10.1371\/journal.pone.0134218","article-title":"Antinuclear antibodies in patients with psoriatic arthritis treated or not with biologics","volume":"10","author":"Silvy","year":"2015","journal-title":"PLoS ONE"},{"key":"2022010916492048500_jfab120-B18","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s12026-013-8410-2","article-title":"Autoantibody induction and adipokine levels in patients with psoriasis treated with infliximab","volume":"56","author":"Lora","year":"2013","journal-title":"Immunol Res"},{"key":"2022010916492048500_jfab120-B19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/jcla.20365","article-title":"Prevalence of autoantibodies in patients of psoriasis","volume":"24","author":"Singh","year":"2010","journal-title":"J Clin Lab Anal"},{"key":"2022010916492048500_jfab120-B20","first-page":"1103","article-title":"Autoimmunity to heterogeneous nuclear ribonucleoprotein A1 in psoriatic patients and correlation with disease severity","volume":"16","author":"Guarneri","year":"2018","journal-title":"J Dtsch Dermatol Ges"},{"key":"2022010916492048500_jfab120-B21","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1016\/j.jaad.2011.06.008","article-title":"The role of antinuclear autoantibodies in patients with psoriasis treated with anti-tumor necrosis factor-alpha agents: a retrospective long-term study","volume":"66","author":"Saraceno","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"2022010916492048500_jfab120-B22","first-page":"401","article-title":"Autoantibodies in psoriatic patients treated with anti-TNF-alpha therapy","volume":"12","author":"Bardazzi","year":"2014","journal-title":"J Dtsch Dermatol Ges"},{"key":"2022010916492048500_jfab120-B23","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1111\/j.1365-2133.2011.10555.x","article-title":"Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction","volume":"165","author":"Hoffmann","year":"2011","journal-title":"Br J Dermatol"},{"key":"2022010916492048500_jfab120-B24","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/bjd.15654","article-title":"No evidence for induction of autoantibodies or autoimmunity during treatment of psoriasis with ustekinumab","volume":"177","author":"Rodriguez-Jimenez","year":"2017","journal-title":"Br J Dermatol"},{"key":"2022010916492048500_jfab120-B25","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jdermsci.2009.08.006","article-title":"Psoriasis patients generate increased serum levels of autoantibodies to tumor necrosis factor-alpha and interferon-alpha","volume":"56","author":"Bergman","year":"2009","journal-title":"J Dermatol Sci"},{"key":"2022010916492048500_jfab120-B26","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2249.2005.02701.x","article-title":"Autoantibodies directed against the protease inhibitor calpastatin in psoriasis","volume":"139","author":"Matsushita","year":"2005","journal-title":"Clin Exp Immunol"},{"key":"2022010916492048500_jfab120-B27","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/cei.13376","article-title":"Serum IFI16 and anti-IFI16 antibodies in psoriatic arthritis","volume":"199","author":"De Andrea","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"2022010916492048500_jfab120-B28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00005-020-00573-7","article-title":"Antibodies to heat shock proteins 90alpha and 90beta in psoriasis","volume":"68","author":"Damasiewicz-Bodzek","year":"2020","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"2022010916492048500_jfab120-B29","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0009-8981(99)00062-5","article-title":"The significance of autoantibodies against oxidatively modified low-density lipoprotein (LDL) in patients with psoriasis","volume":"284","author":"\u00d6rem","year":"1999","journal-title":"Clin Chim Acta"},{"key":"2022010916492048500_jfab120-B30","doi-asserted-by":"crossref","first-page":"390","DOI":"10.5001\/omj.2016.78","article-title":"Is the ratio of antibodies against oxidized LDL to oxidized LDL an indicator of cardiovascular risk in psoriasis?","volume":"31","author":"Sunitha","year":"2016","journal-title":"Oman Med J"},{"key":"2022010916492048500_jfab120-B31","doi-asserted-by":"crossref","first-page":"390","DOI":"10.5114\/ceji.2017.72807","article-title":"The role of anti-citrullinated protein antibodies (ACPA) in the pathogenesis of rheumatoid arthritis","volume":"42","author":"Kurowska","year":"2017","journal-title":"Cent Eur J Immunol"},{"key":"2022010916492048500_jfab120-B32","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/1346-8138.13667","article-title":"Increased circulating anti-alpha6-integrin autoantibodies in psoriasis and psoriatic arthritis but not in rheumatoid arthritis","volume":"44","author":"G\u00e1l","year":"2017","journal-title":"J Dermatol"},{"key":"2022010916492048500_jfab120-B33","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1038\/jid.2008.71","article-title":"Humoral autoimmune responses to the squamous cell carcinoma antigen protein family in psoriasis","volume":"128","author":"El-Rachkidy","year":"2008","journal-title":"J Invest Dermatol"},{"key":"2022010916492048500_jfab120-B34","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1136\/annrheumdis-2020-eular.3698","article-title":"AB0832 identification of native and citrullinated autoantibodies to psoriasis related-antigen PsoP27 in synovial fluids of patients with psoriatic arthritis","volume":"79","author":"Slobodkin","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2022010916492048500_jfab120-B35","doi-asserted-by":"crossref","first-page":"e115424","DOI":"10.1371\/journal.pone.0115424","article-title":"Crossreactive autoantibodies directed against cutaneous and joint antigens are present in psoriatic arthritis","volume":"9","author":"Dolcino","year":"2014","journal-title":"PLoS ONE"},{"key":"2022010916492048500_jfab120-B36","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.3389\/fimmu.2018.01936","article-title":"Anti-LL37 antibodies are present in psoriatic arthritis (PsA) patients: new biomarkers in PsA","volume":"9","author":"Frasca","year":"2018","journal-title":"Front Immunol"},{"key":"2022010916492048500_jfab120-B37","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/art.40830","article-title":"Identification of novel autoantibodies associated with psoriatic arthritis","volume":"71","author":"Yuan","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2022010916492048500_jfab120-B38","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000488672","article-title":"Serum squamous cell carcinoma antigen in psoriasis: a potential quantitative biomarker for disease severity","volume":"234","author":"Sun","year":"2018","journal-title":"Dermatology"},{"key":"2022010916492048500_jfab120-B39","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3109\/08916934.2010.530628","article-title":"The autoantigen Pso p27: a post-translational modification of SCCA molecules","volume":"44","author":"Iversen","year":"2011","journal-title":"Autoimmunity"},{"key":"2022010916492048500_jfab120-B40","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3899\/jrheum.181472","article-title":"Treating psoriatic arthritis to target: defining the psoriatic arthritis disease activity score that reflects a state of minimal disease activity","volume":"47","author":"Perruccio","year":"2020","journal-title":"J Rheumatol"}],"container-title":["The Journal of Applied Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jalm\/article-pdf\/7\/1\/281\/42084021\/jfab120.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jalm\/article-pdf\/7\/1\/281\/42084021\/jfab120.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,9]],"date-time":"2022-01-09T11:50:01Z","timestamp":1641729001000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jalm\/article\/7\/1\/281\/6498240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,1]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1,5]]},"published-print":{"date-parts":[[2022,1,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jalm\/jfab120","relation":{},"ISSN":["2576-9456","2475-7241"],"issn-type":[{"value":"2576-9456","type":"print"},{"value":"2475-7241","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2022,1,1]]}}}